The company's immunomodulation platform, LAMP-Vax, enables nucleic acid immunotherapy (DNA or RNA) to utilize the body's natural . This day-long event includes an Advocacy Summit Liked by Priscilla Fussell In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). Melssen M.,Vaccines targeting helper T cells for cancer immunotherapy. The New Taipei Municipal Hsin Tien Senior High School ( Chinese: ) is a senior high school in Xindian District, New Taipei, Taiwan which was founded in 1992. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. Companies. Hershey, PA & Rockville, MD and Tokyo, Japan. 1K followers 500+ connections. Jan 2006 - Present17 years 2 months. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. Senior Scientist/Scientist II, Formulation Development. ITI-ID Candidate Multiple infectious diseases. People with disabilities who need a reasonable accommodation to apply or compete for employment with Immunomic Therapeutics may request such accommodation(s) by sending an e-mail to:
[email protected]. You will receive a reply to confirm the receipt of your application. We currently have 4 wholly-owned oncology programs, with our lead program in Phase 2 clinical studies for GBM. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy, and autoimmune diseases. Glassdoor gives you an inside look at what it's like to work at Immunomic Therapeutics, including salaries, reviews, office photos, and more. ROCKVILLE, Md.-- ( BUSINESS WIRE )--Immunomic Therapeutics, Inc., ("ITI"), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based . To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. Active, Closed, Last funding round type (e.g. Marques E.T.A., Jr., et al., HIV-1 p55Gag Encoded in the Lysosome-associated Membrane Protein-1 as a DNA Plasmid Vaccine Chimera Is Highly Expressed, Traffics to the Major Histocompatibility Class II Compartment, and Elicits Enhanced Immune Responses. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bo dy's natural biochemistry to develop . All content is posted anonymously by employees working at Immunomic Therapeutics. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform . Juniper Point Ms. Harrison earned a Bachelor of Science in Biochemistry from San Diego State University. Immunomic Therapeutics, Inc. | 2,335 followers on LinkedIn. Founded Date 2015. We have significant capabilities in molecular biology, including nucleic acid vaccine design, immunology, and tumor mouse modeling. We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Clin Cancer Res 2020;26:5297303, Batich K.A.,Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. This is the Immunomic Therapeutics company profile. Claim your Free Employer Profile. Immunomic Therapeutics' nucleic acid vaccines have the . While induction of tumor-reactive CD8+ T cells is a major goal of cancer therapy, CD4+ T cells provide essential support to CD8+ T cells by promoting their expression of cytotoxic effector molecules and increasing their migratory capacity. Announces Proposed Public Offering of Common Stock, Northeastern US Companies With Fewer Than 1000 Employees (Top 10K), Companies With Fewer Than 100 Employees (Top 10K), United States Companies that Exited (Top 10K), Greater New York Area Biotechnology Companies. We provide a professional and challenging work environment where employees can grow and share in the continued success of the company. We provide a professional and challenging work environment . Curr Opin Immunol. Company Type For Profit. Pays for all health and welfare insurance premiums 100%. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. Share this article. Director of Research and Development at Immunomic Therapeutics, Inc. - most recent Rockville, Maryland, United States. Founders Sungwuk Kim. Additionally, our expanded capabilities allow us to work with our corporate partners to better understand and develop the manufacturing process and product testing assays. Contact Email
[email protected]. 2015 Mar 19;519(7543):366-9. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. The initial foray into immuno-oncology was undertaken when ITI decided to support the work of Drs. A $300 million worldwide licensing agreement announced last week between Immunomic Therapeutics and Astellas Pharma to develop treatment for a wide range of allergic diseases, including peanut allergies, is the largest deal ever to come out of Johns Hopkins Technology Ventures, the patent, licensing, and technology . Melody Carey Seed, Series A, Private Equity), Alternate or previous names for the organization, Whether an Organization is for profit or non-profit, General contact email for the organization.
[email protected] -Proceeds to support acceleration of Phase II clinical trial for GBM, advancement of pipeline, including development of COVID-19 vaccine candidate and expansion of opportunities for its UNITE nucleic acid platform-. We now have a well-defined process to take things from ideation to in vivo animal proof of concept studies before handing them off to product development. Company: Melissa Kemp Immunomic Therapeutics
[email protected] 301-968-3501 Media: Amy Conrad Juniper Point
[email protected] 858-366-3243 Contacts SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Clin Cancer Res. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . ITI-3000 is being tested in a Phase 1, open label, First in Human (FIH) study to evaluate the safety, tolerability, and immunogenicity of 4 mg of ITI-3000 in patients with Merkel polyomavirus-positive Merkel cell carcinoma (MCC). The primary mechanism of action of ITI-1000 is to generate a T cell-mediated immune response against malignant glial cells expressing the CMV pp65 protein. I would also like to take the opportunity to sincerely thank Louise Peltier for her leadership over the last seven years and wish her well in her retirement., I am both honored and excited to be joining Immunomic Therapeutics at such a critical point in its growth cycle, said Ms. Harrison. Su Y et al., Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese red cedar atopic subjects: A phase I study. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. The foundation of a successful company is only as strong as the quality of its employee team. In addition to our pipeline, we are also developing through collaborations with academic centers and biotechnology companies the use of the UNITE platform in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. While the presence of the CMV pp65 antigen itself is expected to induce a general effector T cell response, fusion of the antigen to Lysosomal Associated Membrane Protein (LAMP) is intended to compel processing of the antigen through a pathway that presents antigens specifically to CD4+ T cells and results in a robust Th1- type response (Arruda, 2006). GOLDEN, Colo. December 13, 2022 PharmaJet, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with Immunomic Therapeutics, Inc. Biotechnology Research Rockville, MD 2,335 followers A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms ITI-1000 GBM - Cell Therapy. Immunomic Therapeutics investigational UNITEplatform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. The primary mechanism of action of ITI-1000 is to generate a T cell-mediated immune response against malignant glial cells expressing the CMV pp65 protein. The company was founded in 2005 and is based in Lancaster, Pennsylvania. Melissa Kemp ICT has established a broad portfolio of CAR-T products to treat cancer patients. 301-968-3501 Their LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in . Contacts ITI Company Contact: Melissa Kemp
[email protected] 301-968-3501 ITI Media Contact: Melody Carey
[email protected] 917-322-2571 Operating Status Active. This is the Immunomic Therapeutics company profile. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. Immunomic Therapeutics investigational UNITE platform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. Stock ticker symbol (e.g. Immunomic Therapeutics Receives FDA Fast Track Designation for ITI-3000, a pDNA Vaccine, in Development for the Treatment of Merkel Cell Carcinoma November 08, 2022 08:30 AM Eastern Standard Time ITI maintains its headquarters in Rockville, Maryland. We are based at the Translation & Innovation Hub that sits on Imperial College London's 23-acre White City Campus development in west . Join to follow . Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. immunomic therapeutics crunchbase. The UNITE platform can result in a number of downstream effects: CD4+ memory, cytokine production, and a potent antibody response. ImmunoMet Therapeutics is a biopharmaceutical company that develops and commercializes oncology products for cancer patients. The Company has built a large pipeline from UNITE with six oncology programs and two allergy programs. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. It is important to note that, while the mechanism of lysosomal targeting appears to focus on enhancing presentation of antigen to CD4+ T cells and producing a Th1 type CD4+ T cell response (an aspect missing in other platforms), the UNITE platform, as a whole, is believed to induce a broad immune response and can result in enhanced CD8+ T cell responses as well. Immunomic Therapeutics' investigational UNITE platform is founded in a combination of complementary technologies and capabilities: ITI's proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. Edit Lists Featuring This Company Section, Immunomic Therapeutics to Present at Biotech Showcase 2023. Mr. Stamper holds a Master of Biotechnology Enterprise and Entrepreneurship Degree (MBEE) from Johns Hopkins University, a Master of Science Degree in Biologics Engineering from Purdue University, and a Bachelor of Science Degree in Biochemistry from Indiana University. But a few things must happen first. It is one of the few malignancies for which incidence approximates prevalence, as patients almost always . ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI) a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the close of a $61.3M financing led by HLB Co., LTD, a global pharmaceutical company focused on developing novel cancer drugs. ITI-1000 is a cell therapy powered by ITIs UNITE platform that is currently being evaluated in a Phase II clinical trial (ATTAC-II) in collaboration with researchers at the University of Florida (Dr. Duane Mitchell) and Duke University (Dr. John Sampson). Being able to attract someone with so much collective experience, which has resulted in more than 75 regulatory submissions operating in 125 countries, is a real coup for ITI. Types of diversity represented in an organization, specifically of those who are founding members, currently the CEO, or have check-writing abilities in an investment firm. What is health insurance like at Immunomic Therapeutics. For consideration, please send your company information, a copy of your standard search agreement, and references to:
[email protected]. The company held a successful pre-IND meeting earlier this year for ITI-1001 and expects to be able to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) by the end of 2020. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. Hum Vaccin Immunother. 15010 Broschart Dr., Suite 110, Rockville, MD 20850. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. The company was founded in 2005 and is based in Lancaster, Pennsylvania. Chief Scientific Officer (CSO) Immunomic Therapeutics, Inc. Jun 2019 - Present3 years 9 months. ITI-2000 HPV+ Tumors. ITI maintains its headquarters in Rockville, Maryland.